Zepbound coupons & savings
tirzepatide · manufacturer programs, telehealth bundles, discount cards
Jump to section
Lilly offers both a self-pay vial program and a commercial savings card that can dramatically reduce out-of-pocket cost depending on your insurance status.
Your options
- RecommendedManufacturer
LillyDirect Self-Pay (vials)
$299-$449/month (vials or KwikPen, by dose)Eligibility: No insurance required. 2.5 mg $299, 5 mg $399, 7.5-15 mg $449 when refilled within 45 days ($499-$699 if not). Vials and the multi-dose KwikPen only; the single-dose pen is not in the self-pay program.
- Manufacturer
Zepbound Savings Card
as low as $25/monthEligibility: Requires commercial insurance that covers Zepbound; applies to the single-dose pen. Not eligible for Medicare, Medicaid, or other government programs. Savings capped at $100 per 1-month fill and $1,300 per calendar year; program ends December 31, 2026.
⚠ Maximum savings caps apply — check current card terms.
- Telehealth
Ro Body program
from $145/monthEligibility: Branded Zepbound bundled separately when supply allows; otherwise compounded tirzepatide via 503A pharmacy.
Important notes
- Insurance with commercial coverage + savings card is usually the lowest out-of-pocket path.
- Without commercial coverage, LillyDirect Self-Pay vials are the cheapest legal option.
- Vial format requires self-injection from vial + syringe vs the auto-injector pen — minor technique difference.
What Zepbound actually costs you: the four scenarios
Zepbound's list price is almost never what anyone pays. Your real out-of-pocket cost falls into one of four buckets, and knowing which one you are in tells you exactly which program to pursue first.
Scenario 1 — commercial insurance that covers Zepbound: the Zepbound Savings Card is your lever. For the single-dose pen it can bring the copay to as low as $25 per fill, with savings capped at $100 per month and $1,300 per calendar year; the current card runs through December 31, 2026. This is usually the cheapest path of all, but it requires that your plan actually lists Zepbound on its formulary, which many employer plans exclude for weight loss.
Scenario 2 — commercial insurance that does NOT cover Zepbound: you cannot use the savings card (it requires covered commercial insurance), so your real options are LillyDirect self-pay vials or a telehealth bundle. An insurance appeal is worth trying first if you have a qualifying condition, because a successful appeal moves you into Scenario 1.
Scenario 3 — no insurance / self-pay: LillyDirect self-pay ($299-$449/month by dose, as vials or the multi-dose KwikPen) is the cheapest legal branded option; the $449 price for 7.5 mg and up requires a refill within 45 days, otherwise it is $499-$699. You buy directly from Lilly's pharmacy; the single-dose auto-injector pen is not part of the self-pay program.
Scenario 4 — Medicare, Medicaid, or other federal coverage: the Zepbound savings card excludes you. Medicare Part D enrollees may qualify for the Medicare GLP-1 Bridge, which covers the Zepbound KwikPen for $50/month from July 1, 2026 through December 31, 2027. Your path is whatever your plan covers plus, in some cases, the cardiovascular or sleep-apnea medical indications that can unlock coverage a weight-loss-only prescription cannot.
LillyDirect self-pay vials vs the pen: what the price gap buys
Lilly's self-pay prices apply to single-dose vials and the multi-dose KwikPen, not the single-dose auto-injector pen. The single-dose pen is more convenient — a fixed, pre-measured, spring-loaded injection — while the vial requires drawing the dose into a syringe yourself. For most people that is a modest, learnable technique difference, and it is the reason the vial route is meaningfully cheaper.
If needle technique is a real barrier for you, weigh the convenience of the pen against the price gap. Many people find that after the first one or two vial injections the process is routine, and the monthly savings are large enough to justify the small learning curve. If you have dexterity or vision limitations, that calculus can flip — raise it with your prescriber.
The savings-card caps most people miss
The headline '$25' savings-card price assumes your plan's copay is low enough. The card pays at most $100 per 1-month fill and $1,300 per calendar year, so with a $200 copay you pay $100, not $25. It covers up to 13 fills a year and applies only to the single-dose pen.
The current card ends December 31, 2026. Check the terms on zepbound.lilly.com before the new year and budget around your copay minus $100, not the headline figure.
Why 'compounded tirzepatide is cheaper' is a shrinking loophole
For a stretch during the tirzepatide shortage, compounded versions were widely available and often cheaper than branded Zepbound. That window has largely closed: once the FDA declared the shortage resolved, the legal basis for mass-compounding tirzepatide narrowed sharply, and enforcement tightened. Legitimate patient-specific 503A compounding still exists but is priced like a real specialty compound, not a commodity.
Treat any offer of 'compounded tirzepatide' at a suspiciously low, commodity-style price with caution: it may reflect bulk compounding under a shrinking or expired regulatory allowance, and you cannot verify the product's identity, dose, or sterility the way you can with a branded pharmacy fill. The branded self-pay vial route is more transparent and, increasingly, competitive.
Getting the lowest price: the decision order
Work the options in this order. First, confirm whether your commercial plan covers Zepbound (call the number on your card or use an insurance pre-check) — if yes, the savings card usually wins. Second, if it is not covered, try a formulary-exception appeal, especially if you have a qualifying comorbidity like the FDA-approved sleep-apnea or cardiovascular indications. Third, if coverage genuinely is not available, compare LillyDirect self-pay vials against telehealth bundles on total monthly cost including any program fees.
The most expensive mistake is paying full retail because you did not realize a cheaper legal path existed. Every scenario above beats retail, and the difference over a year is thousands of dollars — worth the hour it takes to work through the order once.
Charity and manufacturer assistance: what is actually open
Status read on each program’s own site on September 16, 2026
3 of the 10 programs below were closed to new applicants on that date, including every charity fund that pays toward a weight-loss GLP-1. We have no relationship with any of them and cannot influence an application. Fund status changes without notice, so confirm on the program’s own page before you count on it.
- Closed
TotalAssist (Patient Advocate Foundation; merged with PAN Foundation)
Obesity fund
The catch: This is the one charity fund built for weight-loss drugs, and it is closed. Its own rules also require health insurance that already covers the expense, so a cash-pay patient would not qualify even when it is open.
- Income limit as stated
- Have an income at or less than 300% of the Federal Poverty Level, adjusted for your regional Cost of Living Index (COLI)
- Insurance requirement
- Have health insurance that covers your qualifying expenses (fund list row: “Health insurance (any)”)
- Award
- $1,000 guaranteed award | $2,000 maximum award
- Phone
- 866-512-3861 (Mon–Fri 8:30am–5:30pm ET)
Status checked: Closed to new applicants when we checked the program's own page on September 16, 2026. Source
- Closed
TotalAssist (Patient Advocate Foundation; merged with PAN Foundation)
Type 2 diabetes (T2DM) fund
The catch: Closed, and it was never open to everyone: this fund requires government-insured coverage, so commercially insured and uninsured patients are ineligible. The companion type 2 diabetes health equity fund is closed as well.
- Income limit as stated
- Have an income at or less than 500% of the Federal Poverty Level, adjusted for your regional Cost of Living Index (COLI)
- Insurance requirement
- Have government-insured coverage that covers your qualifying expenses (fund list row: “Government-insured coverage (Medicare, Medicaid, or TRICARE)”)
- Award
- $1,500 guaranteed award | $2,000 maximum award
- Phone
- 866-512-3861 (Mon–Fri 8:30am–5:30pm ET)
Status checked: Closed to new applicants when we checked the program's own page on September 16, 2026. Source
- Open
TotalAssist (program-level rules)
Program-wide eligibility (nearly 150 funds)
The catch: The program runs, but you can only apply to a fund that is open, and both funds that reach GLP-1s — obesity and type 2 diabetes — were closed on the date checked. A closed fund offers a notification sign-up, not a waitlist queue.
- Income limit as stated
- Have a household income of 500% or less than the Federal Poverty Level (FPL) guidelines, adjusted by the Cost-of-Living Index (COLI) for where the patient lives — with the exception: “Household income of 300% or less than the Federal Poverty Level (only our obesity fund)”
- Insurance requirement
- Have active insurance coverage that includes coverage for pharmaceutical products; the required insurance type varies by fund
- Award
- Varies by fund; grants run on an “individual 12-month rolling grant cycle”
- Phone
- 866-512-3861
Status checked: Open on September 16, 2026. Source
- Closed
HealthWell Foundation
Type 2 Diabetes fund
The catch: HealthWell has no obesity or weight-management fund at all, so a weight-loss prescription has no route here. The type 2 diabetes fund is the only one that reaches a GLP-1, and it is closed: “This fund is temporarily closed to new patients due to lack of sufficient funding.”
- Income limit as stated
- 300–500% of the Federal Poverty Level (fund page); program-wide, “up to 400 or 500 percent of the Federal Poverty Level (somewhat more in cities where the cost of living is higher)”
- Insurance requirement
- “some form of health insurance (private insurance, Medicare, Medicaid, TriCare, etc.) that covers part of the cost of your treatment”; “Drug discount cards do not qualify as insurance.”
- Award
- $1,000 per patient, grant period 12 months
- Phone
- (800) 675-8416 (Mon–Fri 9am–5pm ET)
Status checked: Closed to new applicants when we checked the program's own page on September 16, 2026. Source
- Open
Novo Nordisk Patient Assistance Program (PAP)
Manufacturer patient assistance program (free medicine)
The catch: Ozempic is the only GLP-1 on the product list. Wegovy and Saxenda are not on it, so there is no free-medicine route to a branded obesity GLP-1 from Novo Nordisk. For Ozempic the program takes uninsured patients only, at or below 200% of the federal poverty level.
- Income limit as stated
- Ozempic (uninsured): “Total household income must be at or below 200% of the federal poverty level”; insulins and all other products: “Total household income must be at or below 400% of the federal poverty level”
- Insurance requirement
- Must have Medicare or no insurance; private or commercial insurance makes a patient ineligible. For Ozempic, uninsured patients only — Medicare Part D patients are no longer eligible for Ozempic through PAP.
- Award
- Medicine at no cost; approval lasts 12 months for uninsured patients, through the end of the calendar year for Medicare patients
- Phone
- 1-866-310-7549 (Mon–Fri 8am–8pm ET)
Status checked: Open on September 16, 2026. Source
- Open
Lilly Cares Foundation
Lilly Cares Patient Assistance Program
The catch: The only GLP-1 offered is Trulicity, a type 2 diabetes drug. Zepbound and Mounjaro appear in no medication group and on no Available Medications page, so tirzepatide has no free-medicine route here. Private commercial insurance disqualifies.
- Income limit as stated
- Group 1 Medications (at or below 300% FPL); Group 2 Medications (at or below 400% FPL); Group 3 & Group 4 Medications (at or below 500% FPL) — 2026 FPL guidelines. Household of 1/2/3/4 for Group 1: $47,880 / $64,920 / $81,960 / $99,000.
- Insurance requirement
- For Group 1, 2 and 3 medications, which includes Trulicity: “1) You have no insurance, or 2) you have Medicare Part D (not applicable to infused medications), or 3) you have Medicare Part B but have no supplemental or secondary insurance”
- Award
- Free medication; enrollment generally lasts 12 months or to the end of the enrollment period
- Phone
- 1-800-545-6962
Status checked: Open on September 16, 2026. Source
- Open
Patient Advocate Foundation
Case Management Services & MedCareLine; Financial Aid Funds
The catch: Case management is advocacy, not money: it does not pay for medication. It is worth a call for an insurance denial or appeal. The grant arm is TotalAssist, whose obesity and type 2 diabetes funds are closed.
- Income limit as stated
- No income threshold is published for case management; TotalAssist income limits apply to grants
- Insurance requirement
- No insurance requirement is stated for advocacy; case management is offered to patients “facing a chronic, life-threatening or debilitating diagnosis”
- Award
- Case management carries no grant; TotalAssist grants vary by fund
- Phone
- Case Management (800) 532-5274 (Mon–Fri 8:30am–5pm ET); TotalAssist (866) 512-3861; Financial Aid Funds (855) 824-7941
Status checked: Open on September 16, 2026. Source
- Directory only
NeedyMeds
Information directory and free drug discount card
The catch: NeedyMeds awards no money. It lists other people's programs and issues a discount card — and a discount card is not insurance, which matters because HealthWell states “Drug discount cards do not qualify as insurance.” for its own eligibility.
- Income limit as stated
- None for the discount card: “Can be used by anyone — no financial, age, or residency restrictions”
- Insurance requirement
- None; the card is usable with or without insurance
- Award
- No grant. The card is advertised as “Save up to 80%” on prescriptions.
- Phone
- 800-503-6897 (toll-free helpline)
Status checked: Directory only on September 16, 2026. Source
- Directory only
RxAssist
Directory of patient assistance programs
The catch: A lookup tool, not a funder: no money, no grants, no application, and no patient helpline published on the site. Use it to find manufacturer programs, not to pay for a prescription.
- Income limit as stated
- None — RxAssist awards nothing; income rules belong to the programs it lists
- Insurance requirement
- None stated
- Award
- No award; directory only
- Phone
- No patient helpline published on the site
Status checked: Directory only on September 16, 2026. Source
- Open
AZ&Me Prescription Savings Program (AstraZeneca)
Manufacturer patient assistance program
The catch: No GLP-1 for obesity is offered by this program, and its two diabetes drugs stopped taking new patients: “Effective May 1, 2026, the AZ&Me program will no longer accept new patients for FARXIGA and XIGDUO XR”. Any commercial insurance disqualifies.
- Income limit as stated
- Annual adjusted gross income must be at or below 300% of the Federal Poverty Level (FPL) for Primary and Specialty Medications; 500% of FPL for Rare Disease Medications
- Insurance requirement
- “Not have any commercial (private or employer-sponsored) insurance or government insurance other than Medicare”
- Award
- Medication at no cost, up to a 90-day supply per fill
- Phone
- 1-800-292-6363 (Mon–Fri 9:00am–6:00pm ET)
Status checked: Open on September 16, 2026. Source
Manufacturer copay cards. The Zepbound, Mounjaro, Wegovy and Ozempic savings cards all exclude patients in a government program. The Wegovy terms put it plainly: “Patient is not eligible if he/she is enrolled in any federal or state health care program with prescription drug coverage, such as Medicaid, Medicare, VA, DOD, TRICARE, or any similar federal or state health care program”. If you are on Medicare or Medicaid, the $25 card price is not available to you, whatever the ad says.
Compounded GLP-1s. No program reviewed covers compounded semaglutide or tirzepatide. TotalAssist limits approved medications to products that are “FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines”. Manufacturer programs supply only their own branded products.
Telehealth prescriptions. No program reviewed publishes a telehealth exclusion on its own site. Where a prescription was written is not something these programs ask about in their published rules.
More on Zepbound
Frequently asked
What's the cheapest way to get Zepbound?+
Based on the programs currently tracked, the lowest sticker price for Zepbound is "Zepbound Savings Card" at as low as $25/month. Eligibility varies by program — check the requirements for each option above before counting on a price.
Does insurance cover Zepbound?+
Insurance coverage for Zepbound depends on the plan and indication. Many commercial plans cover tirzepatide for FDA-approved uses with prior authorization; off-label use is rarely covered. Check your formulary or run your plan through our insurance coverage tool.
Are coupons for Zepbound legitimate?+
Manufacturer programs from Zepbound's maker and federally registered patient assistance foundations are legitimate. Be cautious with discount cards that promise prices far below retail without verifying the dispensing pharmacy is licensed in your state.
What's the best option for Zepbound right now?+
Editorial pick: LillyDirect Self-Pay (vials) at $299-$449/month (vials or KwikPen, by dose). No insurance required. 2.5 mg $299, 5 mg $399, 7.5-15 mg $449 when refilled within 45 days ($499-$699 if not). Vials and the multi-dose KwikPen only; the single-dose pen is not in the self-pay program. This is a starting point; your situation may favor a different program based on insurance and clinical eligibility.